Hong-Ming Hu: Scaling TCR-T for solid tumors through ImmuXell's partnership with IRO®

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Hong-Ming Hu, Founder and Chief Scientific Officer of ImmuXell Biotech, together with Ori's Founder and Chief Scientific Officer, Farlan Veraitch, to explore what it takes to bring TCR-T cell therapy to solid tumors, from discovery science to the first patient dosed.Drawing on more than three decades in cancer immunology and adoptive cell therapy, Hong-Ming shares how a novel retroviral vector, one-step transduction and automated manufacturing on Ori's IRO® platform took ImmuXell from process installation to first patient dosed in around four months. Together with Farlan, they unpack the economics behind cell therapy's cost of goods, the case for de-skilled, decentralized manufacturing, and why flexible routes like China's IIT pathway, paired with smarter, data-rich process development, are essential to widen patient access and move solid-tumor cell therapy from a handful of patients to many.Further InformationConnect with Hong-Ming Hu: https://www.linkedin.com/in/hong-ming-hu-a546687/Connect with Farlan Veraitch: https://www.linkedin.com/in/farlan-singh-veraitch-a677112/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Ken Harris, CEO of Omnia Bio and former healthcare lead at Amazon Web Services, to explore what it will take to scale CAR-T from hundreds to millions.Drawing on 35 years in healthcare, Ken shares how AI, automation, and digital infrastructure can help streamline manufacturing and support consistent delivery. They unpack the economic reality behind CGT access, the need for smarter clinical trial design, and why a more integrated system is essential to move beyond bespoke solutions.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, Head of Cell and Gene Advanced Therapies at McKesson, to explore how advanced therapies can be delivered through the same systems that support other complex medicines.Joe shares what he has learned from decades of speciality drug distribution and how those lessons are now being applied to cell and gene therapies at McKesson. From managing cold chain logistics to preparing community sites for treatment delivery, he reflects on what it takes to build practical, scalable systems that meet real-world needs. Together, he and Jason discuss the shift away from bespoke solutions and the value of adapting proven infrastructure to help CGTs reach more patients, more efficiently.Watch on YouTube: https://youtu.be/uUqX3aFKBrsFurther Information⁠Connect with Joe⁠

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Jonathan Gluck, an award-winning journalist and author of An Exercise in Uncertainty, for a deeply personal conversation about illness, identity, and the evolving promise of cell therapy.Jonathan shares his 20-year journey with multiple myeloma, from the early days of treatment to receiving CAR-T therapy, and reflects on what it means to live – and write – through chronic uncertainty. Together, they explore the patient experience behind clinical progress, and the human stories that often get lost between endpoints and approvals.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes John Khoury, Founder of Project Farma, to unpack how the standards for advanced therapies are shifting.John reflects on why infrastructure planning, automation, and comparability studies can’t be left until late-stage development. They explore how CGT companies can reduce manufacturing risk by running development activities in parallel, why early investment in platform approaches matters, and how outdated assumptions about regulatory flexibility may be slowing progress. For developers aiming to compete at scale, these early decisions are quickly becoming non-negotiable.Connect with John: https://www.linkedin.com/in/john-khoury-017b592/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Warner Biddle, CEO of Kyverna Therapeutics, to explore how autologous CAR-T therapies can be delivered safely, efficiently, and at scale in autoimmune disease.Warner shares Kyverna’s approach to designing a commercially viable treatment model — one that prioritizes outpatient care, streamlined manufacturing, and real-world practicality. They discuss what it means to bring complex therapies into community settings, how Kyverna is tailoring its rollout strategy by indication, and why the future of CAR-T in autoimmune disease depends as much on delivery as it does on data.Connect with Warner: https://www.linkedin.com/in/warnerbiddle/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions are evolving to meet the demands of early-phase CGT trials.Kumar shares how Moffitt is building flexible, end-to-end infrastructure that supports the full development cycle – from translational research to GMP manufacturing. Together, they explore how tighter integration between scientists, clinicians, and operational teams can accelerate first-in-human trials, why academic centres play a crucial role in advancing CGTs, and how the right partnerships can extend institutional capabilities.Connect with Kumar: https://www.linkedin.com/in/lavakumar-karyampudi/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planning, automation, and economic discipline can help scale the impact of cell therapies.Henrik draws on his experience in both biologics and cell therapy to discuss how platform thinking, target product profiles, and cost-of-goods modelling can be applied earlier in development. Together, they reflect on the pitfalls of rushing to clinic without a viable manufacturing strategy, the shift in investor expectations, and why adapting lessons from biologics could help CGT companies avoid costly detours on the path to commercial success.Connect with Henrik

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Arsalan Arif, founder of Endpoints News, for a wide-ranging conversation on the business of biotech. From his early days bootstrapping a media company to Endpoints’ recent partnership with the Financial Times, Arsalan shares his journey and reflections on what it takes to build trust in an evolving industry.Together, they unpack today’s cell and gene therapy landscape, where clinical success alone isn’t enough. Arsalan offers his perspective on investor sentiment, why scaling remains the biggest challenge in CGT, and how economic models, not efficacy, will shape the next chapter of growth.Learn more about Arsalan: https://www.linkedin.com/in/arsalanarif/

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Dr. Julie Allickson, Chief Technology Officer for Mayo Clinic's Center for Regenerative Biotherapeutics. With over 30 years pioneering regenerative medicine - from early bone marrow transplant programs to today's cutting-edge cell and gene therapies - Julie shares her journey and insights on translating innovative therapies from discovery to clinical impact.Together, they explore how academic medical centers are evolving to bridge the gap between research and commercialization through integrated manufacturing capabilities, multi-site clinical trials, and strategic partnerships. Julie discusses Mayo Clinic's approach to managing 30+ clinical trials across three sites, the critical role of automation and AI in reducing costs and improving scalability, and why thinking about commercial viability early in development is essential widespread patient access.Learn more: https://www.linkedin.com/in/julie-g-allickson-phd-76129062/